La mucoviscidose est une maladie génétique présentant des altérations ioniques causées par une protéine membranaire défectueuse ou inexistante la CFTR entraînant des perturbations métaboliques. Nous sommes intéressés à l’altération du métabolisme des acides gras polyinsaturés (AGPI) n-3 et n-6, caractérisé par une déficience en acides linoléique (LA) et docosahexaénoïque (DHA) et une élévation de l’acide arachidonique (AA). Ce déséquilibre peut être préjudiciable à l’état des patients du fait du rôle clé de certains AGPI à différents niveaux de la vie. Nos travaux ont portés sur la recherche des bénéfices d’un vecteur riche en un AGPI n-3 d’intérêt, le DHA, dans le contexte de la mucoviscidose à travers deux approches : une approche par supplémentation réalisée chez un modèle murin présentant la mutation la plus répandue chez les patients, et une approche sur un modèle d’entérocyte humain afin d’étudier de façon plus approfondie l’intérêt du supplément sur la fonctionnalité cellulaire (absorption des nutriments lipidiques). Nos résultats nous ont conduits à différentes conclusions : les souris delF508 nourries avec du Peptamen Junior présentent une perturbation du métabolisme des n-6 (LA, AA) dès l’âge de 3 mois ; cette altération apparaît mais plus tard sous régime standard. Par contre, quelque soit le régime alimentaire notre modèle ne développe pas de déficience en DHA jusqu’à l’âge d’1 an. L’évolution du statut en AGPI n-6 est donc dépendante du régime et de l’âge. L’apport de glycérophospholipides enrichis en DHA administré à faible dose permet de corriger les perturbations en AGPI n-6 et d’augmenter le rapport en DHA/AA dans la plupart des organes. Ce vecteur s’avère potentiellement intéressant en nutrithérapie chez le patient. Un enrichissement physiologique en DHA de l’entérocyte ne modifie pas ses capacités absorptives qui sont plutôt régulées par le type de particules véhiculant les produits de lipolyses, micelles de sels biliaires versus liposomes. / Cystic fibrosis is a genetic disease showing ionic alterations, caused by an absent or defective membrane protein CFTR leading to metabolic disturbances. We are interested in n-6 and n-3 polyunsaturated fatty acid (PUFA) metabolism alteration characterized by a linoleic (LA) and docosahexaenoic (DHA) acids deficiency and high level of arachidonic acid (AA). This imbalance can affect patient health due to the key role of some PUFAs in different levels of life. Our studies focused on finding the benefits of a vector enriched in one interesting n-3 PUFA, DHA, in context of cystic fibrosis, through two approaches: a nutritional supplementation conducted in a mouse model with the most common mutation of cystic fibrosis patients, and an approach on a model of human enterocyte to investigate more thoroughly the effect of the vector on cell functionality (absorption of lipid nutrients). Our results led us to different conclusions: del F508 mice fed with Peptamen Junior have a metabolic disorder of the n-6 PUFA (LA, AA) at the age of 3 months, but this alteration appears later under standard regime . But, whatever the diet, our model does not develop a DHA deficiency to the age of 1 year. The changing status of n-6 is dependent on diet and age. Glycerophospholipids enriched in DHA given at low doses can correct disturbances in PUFA n-6 and increase the DHA/AA ratio in most organs. This vector is potentially interesting for a patient nutritherapy. A physiological DHA enrichment of enterocyte does not alter its absorption capacity, which is rather regulated by the type of particles carrying the lipolysis products, bile salt micelles versus liposomes.

La dysfonction endothéliale vasculaire, processus majeur initiant l’athérosclérose, est étroitement liée à l’altération de la synthèse et/ou biodisponibilité du monoxyde d’azote (NO), dont l’arginine est le précurseur. Elle apparait aussi dès la phase postprandiale après un repas gras et sucré. Chez des sujets avec des facteurs de risque cardiométabolique, une supplémentation orale en arginine a un effet bénéfique sur des fonctions associées au NO. Aucune donnée ne permet cependant de lier la mise à disposition de l’arginine et la synthèse de NO, en situation normale ou de risque cardiométabolique. De plus, peu d’études ont étudié l’effet d’une supplémentation en arginine, dans un contexte nutritionnel (faible dose et libération lente) chez des sujets avec des facteurs de risque cardiométabolique. Ce travail vise donc à évaluer l’effet d’une supplémentation nutritionnelle en arginine, sur le métabolisme de l’arginine et la fonction endothéliale (FE), chez des sujets sains présentant des facteurs de risque cardiométabolique. Dans une première étude clinique, nous avons ainsi comparé la biodisponibilité de l’arginine ingérée et son utilisation pour la synthèse de NO, selon la présence de facteurs de risque cardiométabolique, et selon qu’elle était consommée sous une forme à libération immédiate (LI) ou sous une forme à libération prolongée (LP), mimant la mise à disposition naturelle de l’arginine alimentaire. Puis, dans une deuxième étude clinique, nous avons étudié l’effet de la supplémentation en arginine LP sur la FE à jeun et sur son altération postprandiale, chez des sujets sains présentant des facteurs de risque cardiométabolique; et si cet effet pourrait varier selon leur argininémie basale. Ce travail de thèse a ainsi mis en évidence une utilisation de l’arginine ingérée plus élevée pour la synthèse de NO chez les sujets avec des facteurs de risque cardiométabolique, et plus élevée avec la forme LP qu’avec la forme LI, en particulier chez ces sujets à risque. La deuxième étude, quant à elle, a révélé que les effets de la supplémentation en arginine-LP variaient selon l’argininémie basale des sujets présentant des facteurs de risque cardiométabolique. Chez les sujets avec une argininémie basale relativement plus faible, l’arginine-LP a atténué la diminution postprandiale de la FE et a conduit à une FE significativement meilleure à la fin de la période postprandiale. / Vascular endothelial dysfunction, the hallmark of early atherosclerosis, results from an impairment of the synthesis and/or bioavailability of nitric oxide (NO), the precursor of which is arginine. Endothelial dysfunction is also known to be induced transiently by a high-fat meal. In subject with cardiometabolic risk factors, oral arginine supplementation has a beneficial effect on NO-related physiological functions. However, no data relates the availability of arginine to the synthesis of NO in normal or cardiometabolic risk condition. In addition, few studies only have investigated the effect of arginine supplementation in a nutritional context (low dose and slow release) in subjects with cardiometabolic risk factors. This work aims to evaluate the effect of a nutritional arginine supplementation, on the arginine metabolism and endothelial function in healthy subjects with cardiometabolic risk factors. In a first clinical study, we have compared the bioavailability of oral arginine and its utilization for NO synthesis, as a function of the presence of cardiometabolic risk factors, and as a function of the form of release (immediate release, IR, as free arginine, or sustained release, SR, which mimics the slow release of dietary arginine). Then, in a second clinical study, we studied the effect of SR-arginine supplementation on fasting endothelial function and its postprandial alteration in healthy subjects with cardiometabolic factors. A further aim was to investigate whether this effect may vary according to the baseline arginine status of subjects. This thesis work has demonstrated a higher utilization of oral arginine for NO synthesis in subjects with cardiometabolic risk factors, and a higher utilization with the SR form, particularly in these subjects at risk. As to the second study, it showed that the SRarginine supplementation effects largely varied with baseline fasting arginine concentration of subjects with cardiometabolic risk factors. In subjects with a relatively lower baseline arginine concentration, SR-arginine attenuated the decrease in postprandial endothelial function and led to a significantly higher endothelial function at the end of the postprandial period.

Introduction: Sodium chloride supplementation in saltwasting congenital adrenal hyperplasia (CAH) is generally recommended in infants, but its implementation in routine care is very heterogeneous. Objective: To evaluate oral sodium chloride supplementation, growth, and hydrocortisone and fludrocortisone dose in infants with salt-wasting CAH due to 21-hydroxylase in 311 infants from the AQUAPE CAH database. Results: Of 358 patients with classic CAH born between 1999 and 2015, 311 patients had salt-wasting CAH (133 females, 178 males). Of these, 86 patients (27.7%) received oral sodium chloride supplementation in a mean dose of 0.9 ± 1.4 mmol/kg/day (excluding nutritional sodium content) during the first year of life. 225 patients (72.3%) were not treated with sodium chloride. The percentage of sodium chloride-supplemented patients rose from 15.2% in children born 1999–2004 to 37.5% in children born 2011–2015. Sodium chloride-supplemented and -unsupplemented infants did not significantly differ in hydrocortisone and fludrocortisone dose, target height-corrected height-SDS, and BMI-SDS during the first 2 years of life. Conclusion: In the AQUAPE CAH database, approximately one-third of infants with salt-wasting CAH receive sodium chloride supplementation. Sodium chloride supplementation is performed more frequently in recent years. However, salt supplementation had no influence on growth, daily fludrocortisone and hydrocortisone dose, and frequency of adrenal crisis.

La anemia en gestantes es un problema de salud pública importante a nivel mundial. Según la prevalencia registrada, en Perú persiste como un problema moderado. La pobre adherencia a la suplementación oral de hierro es una de las principales barreras para la efectividad de esta intervención. El objetivo del presente estudio fue determinar la variación de la adherencia a la suplementación oral de hierro en el tiempo y los factores asociados a esta. Para ello, se reanalizó la base de datos de la vigilancia centinela: “Estudio de adherencia a la suplementación con Hierro durante la gestación en las direcciones de salud de Apurímac y Ayacucho” de la Dirección General de Epidemiología (DGE), el cual tuvo un diseño de cohorte prospectiva longitudinal. Se realizó un análisis descriptivo de las 416 gestantes registradas y un análisis bivariado y multivariado en base a 376 gestantes. Se identificaron las variables sociodemográficas, gestacionales, relacionadas a la suplementación en el embarazo anterior y actual. Para el análisis de los factores asociados a la adherencia se usó el modelo GEE. En la segunda y tercera visita de seguimiento la adherencia incrementó en 4% y 8%, mientras que en la quinta y sexta, se redujo en 8% y 20,6%, respectivamente. Los factores que redujeron la adherencia fueron: falla en la dispensación (25, 3%), náuseas (9,5%), interacción de náuseas y vómitos (13,5%), y no le cae bien el suplemento (11%). En conclusión, la adherencia disminuye con el tiempo y los factores relacionados al suplemento y la falla en la distribución se relacionan a la reducción de esta / Anemia in pregnant women is a major public health problem worldwide. According to the registered prevalence, in Peru it persists as a moderate problem. Poor adherence to oral iron supplementation is one of the main barriers to the effectiveness of this intervention. The aim of this study was to determine the variation in adherence to oral iron supplements over time and the factors associated with it. To do this, the sentinel surveillance database of the "Study of Adherence to Iron Supplementation During Pregnancy in the Health Directions of Apurimac and Ayacucho", of general directorate of epidemiology (DGE), a longitudinal prospective cohort, was reanalyzed. A descriptive analysis of the 416 registered pregnant women and a bivariate and multivariate analysis based on 376 pregnant women was carried out. Sociodemographic, gestational, supplementation in the previous and current pregnancy variables were identified. For the analysis of the factors associated with adherence, the GEE model was used. At the second and third follow-up visit, adherence increased by 4% and 8%, while at the fifth and sixth, it decreased by 8% and 20,6%, respectively. The factors that reduced adherence were: dispensing failure (25,3%), nausea (9,5%), interaction of nausea and vomiting (13,5%), and did not like the supplement (11%). In conclusion, adherence decreases with time and the factors related to the supplement and the failure in the distribution are related to its reduction. / Tesis

Department of Nutrition / MSCPNT

Changes in bone and mineral metabolism and the role of vitamin D in very low birth weight infants. Firstly, the aim of dissertation work was to estimate physiological parathyroid hormone (PTH) levels and their relationship with bone metabolism parameters in otherwise healthy preterm newborns with birth weight 1000-1500 g. Secondly, to evaluate vitamin D status in mothers and their very low birth weight infants (VLBW) at birth and at discharge with currently recommended supplementation of vitamin D. Thirdly, to compare clinical outcomes of VLBW infants with 25-hydroxy vitamin D [25(OH)D] levels ≤ and > 25 nmol/l in umbilical cord blood and finally to evaluate umbilical cord vitamin D as a risk factor for respiratory distress syndrome in preterm infants. It is a set of prospective observational studies involving immature newborns with birth weight below 1500 g. The parameters of mineral and bone metabolism were analysed in umbilical cord blood and newborn serum and urine during hospitalisation (PTH, 25-hydroxy vitamin D, S-Ca, S-P, ALP, U-Ca, U-P) and in pregnant women before delivery (25-hydroxy vitamin D). Bone mineralization was evaluated by bone densitometry. In a pilot study, from the total 134 examined serum samples for PTH levels the estimated reference range was 1.6 - 9.3 pmol/l. From the...

Phosphatidylserine (PS) is an endogenously occurring phospholipid that has been shown to have cognition and mood enhancing properties in humans, possibly through its role as an enzyme co-factor in cellular signal transduction. Specifically, PS has been identified as activator of classical isoforms of protein kinase C, an enzyme known to be involved in the growth and differentiation of neural cells, and is therefore thought to play a role in the protection of neurons. The purpose of this study was to examine the effects of supplementation with PS and caffeine on measures of cognition, reaction time and mood prior to and following an exercise stress. Twenty, healthy, resistance trained males (17) and females (3) (mean ± SD; age: 22.75 ± 3.27 yrs; height: 177.03 ± 8.44cm; weight: 78.98 ± 11.24kg; body fat%: 14.28 ± 6.6), volunteered to participate in this randomized, double-blind, placebo-controlled study. Participants were assigned to a PS group (400mg/day PS; 100mg/day caffeine, N=9) or PL (16g/day Carbs, N=11) delivered in the form of 4 candy chews identical in size, shape and color. Subjects performed an acute bout of full body resistance exercise, prior to (T1) and following 14 days of supplementation (T2). Measures of reaction time (Dynavision® D2 Visuomotor Training Device), cognition (Serial Subtraction Test, SST), and mood (Profile of Mood States, POMS) were assessed immediately before and following resistance exercise in both T1 and T2. Data was analyzed using two-way ANCOVA and repeated measures ANOVA. Supplementation with 400mg PS and 100mg caffeine did not have a significant impact upon measures of reaction time or cognition between groups at baseline or following acute resistance exercise. However, there was a non-significant trend to the attenuation of fatigue iv between groups, following acute resistance exercise (p = 0.071). Interestingly, our data suggests that acute resistance exercise alone may improve cognitive function. Although more research is necessary regarding optimal dosage and supplementation duration, the current findings suggest that supplementation 400mg/day PS with 100mg/day caffeine may attenuate fatigue following acute resistance exercise. It is possible that the lack of significance may be the result of both an inhibition of the PS activated pathway and a withdrawal effect from caffeine.

No description available.

No description available.

Capillary electrophoresis mass spectrometry (CE-MS) is a versatile instrumental method for metabolomics, which allows for comprehensive metabolite profiling of volume-limited biological specimens in order to better understand the molecular mechanisms associated with chronic diseases, including an alarming epidemic of obesity worldwide. Multiplexed CE separations enable high-throughput metabolite screening with quality assurance to prevent false discoveries when combined with rigorous method validation, robust experimental designs, complementary statistical methods, and high-resolution tandem mass spectrometry (MS/MS) for unknown metabolite identification. In this thesis, multiplexed CE-MS technology is applied for both targeted and untargeted metabolite profiling of various biological fluids, including covalently bound thiol-protein conjugates, as well as free circulating metabolites in serum and plasma, and excreted/bio-transformed compounds in urine due to complex host-gut microflora co-metabolism. This work was applied to characterize aberrant metabolic responses of obese subjects in response to dietary challenges, and measure the benefits of dietary interventions that reduce adiposity without deleterious muscle loss. Chapter 2 presents, a simple, sensitive yet robust analytical protocol to expand metabolome coverage in CE-MS for the discovery of labile protein thiols in human plasma using a rapid chemical derivatization method based on N-tert-butylmaleimide (NTBM). Chapter 3 describes targeted metabolite profiling of serum and plasma to investigate the differential metabolic responses between healthy and unhealthy obese individuals before and after consumption of a standardized high-caloric meal, respectively. Chapter 4 of this thesis describes an untargeted metabolite profiling strategy for urine using multisegment-injection (MSI)-CE-MS for elucidating the effects of protein supplementation following a short-term dietary weight-loss intervention study. This work revealed six urinary metabolites that were classified as top-ranking treatment response biomarkers useful for discriminating between subjects consuming carbohydrate (control), soy, and whey supplemented diets. In summary, this thesis demonstrated the successful implementation of multiplexed CE-MS technology for biomarker discovery in nutritional-based metabolomic studies as required for more effective treatment and prevention of obesity for innovations in public health. / Thesis / Doctor of Philosophy (PhD)